Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms

Brain Research

Volumn 1471, Issue , 2012, Pages 13-22

  Kumar, Anil ^a   Sharma, Neha ^a   Gupta, Amit ^a   Kalonia, Harikesh ^a   Mishra, Jitendriya ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Inflammatory cytokine; Intrastriatal; Neuro inflammation; Oxidative stress; Parkinson's disease; Statin

Indexed keywords

ATORVASTATIN; INTERLEUKIN 6; MITOCHONDRIAL ENZYME; OXIDOPAMINE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; LOCOMOTION; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; MITOCHONDRIA; MOTOR ACTIVITY; NADH DEHYDROGENASE; NITRITES; OXIDOPAMINE; PARKINSONIAN DISORDERS; PYRROLES; RATS; RATS, WISTAR; SIMVASTATIN; TETRAZOLIUM SALTS; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 84864662279     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.06.050     Document Type: Article

References (58)

1. O. Aktas, S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, and F. Zipp Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin J. Exp. Med. 197 6 2003 725 733 (Pubitemid 36350867)
2. T. Bandoh, E.F. Sato, H. Mitani, A. Nakashima, K. Hoshi, and M. Inoue Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity Biol. Pharm. Bull. 26 6 2003 818 822 (Pubitemid 39655302)
3. P. Bar-On, L. Crews, A.O. Koob, H. Mizuno, A. Adame, B. Spencer, and E. Masliah Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease J. Neurochem. 105 5 2008 1656 1667 (Pubitemid 351678486)
4. S.B. Berman, and T.G. Hastings Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease J. Neurochem. 73 1999 1127 1137 (Pubitemid 29395471)
5. F. Blandini, M.T. Armentero, and E. Martignoni The 6-hydroxydopamine model: news from past Parkinsonism Relat. Disord. 14 2008 S124 S129
6. M.L. Block, and J.S. Hong Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism Prog. Neurobiol. 76 2005 77 98 (Pubitemid 41242883)
7. G. Boka, P. Anglade, D. Wallach, F. Javoy-Agid, Y. Agid, and E.C. Hirsch Immunocytochemical analysis of tumour necrosis factor and its receptor in Parkisnon's disease Neurosci. Lett. 172 1994 151 154 (Pubitemid 24178765)
8. L. Broom, L. Marinova-Mutafchieva, M. Sadeghian, J.B. Davis, A.D. Medhurst, and D.T. Dexter Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease Free Radic. Biol. Med. 50 5 2011 633 640
9. L. Chen, W.H. Haught, B. Yang, T.G. Saldeen, S. Parathasarathy, and J.L. Mehta Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine J. Am. Coll. Cardiol. 30 1997 569 575 (Pubitemid 27339340)
10. D.K. Choi, S. Pennathur, C. Perier, K. Tieu, P. Teismann, D.C. Wu, V. Jackson-Lewis, M. Vila, J.P. Vonsattel, J.W. Heinecke, and S. Prezedborski Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice J. Neurosci. 25 2005 6594 6600 (Pubitemid 40995291)
11. R. Deumens, A. Blokland, and J. Prickaerts Modeling Parkinsons disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 2002 303 317 (Pubitemid 34634286)
12. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
13. A. Ghosh, A. Roy, J. Matras, S. Brahmachari, H.E. Gendelman, and K. Pahan Simvastatin inhibits the activation of p21 ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease J. Neurosci. 29 2009 13543 13556
14. Y. Glinka, M. Gaseen, and M.B. Youdim Mechanism of 6-hydroxydopamine neurotoxicity J. Neural. Transm. Suppl. 50 1997 55 66 (Pubitemid 27055928)
15. A.G. Gornall, C.J. Bardawill, and M.M. David Determination of serum proteins by means of the biuret reaction J. Biol. Chem. 177 1949 751 766
16. L.C. Green, D.A. Wagner, J. Glogowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannebaum Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids Ann. Biochem. 126 1982 131 138 (Pubitemid 13203451)
17. A. Gupta, A. Dhir, A. Kumar, and S.K. Kulkarni Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats Pharmacol. Biochem. Behav. 94 2009 219 226
18. F. Hefti, E. Melamed, and R.J. Wurtman Partial lesions of dopaminergic nigrostriatal system in rat brain: biochemical characterization Brain Res. 195 1980 123 137 (Pubitemid 10077835)
19. R. Heikkila, and G. Cohen Inhibition of biogenic amine uptake by hydrogen peroxide: a mechanism for toxic effects of 6-hydroxydopamine Science 172 1971 1257 1258
20. M.C. Hernandez-Romero, S. Arguelles, R.F. Villaran, R.M. de Pablos, and M.J. Delgado-Cortes Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide J. Neurochem. 105 2008 445 459 (Pubitemid 351490015)
21. E.C. Hirsch, S. Hunot, P. Damier, and B. Faucheux Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44 2002 S115 120
22. X. Huang, H. Chen, W.C. Miller, R.B. Mailman, J.L. Woodward, P.C. Chen, D. Xiang, R.W. Murrow, Y.Z. Wang, and C. Poole Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease Mov. Disord. 22 2007 377 381 (Pubitemid 46569693)
23. H. Kalonia, P. Kumar, and A. Kumar Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats. Behav. Brain Res. 216 1 2011 220 228
24. M.M. Khan, A. Ahmad, T. Ishrat, M.B. Khan, M.N. Hoda, G. Khuwaja, S.S. Raza, A. Khan, H. Javed, K. Vaibhav, and F. Islam Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease Brain Res. 1328 2010 139 151
25. 2-independent glutamate release rates from depolarized synaptosomes J. Neurochem. 106 2008 826 834
26. T.E. King, and R.L. Howard Preparations and properties of soluble NADH dehydrogenases from cardiac muscle Methods Enzymol. 10 1967 275 284
27. E.L. Lane, S.C. Cheetham, and P. Jenner Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp. Neurol. 197 2 2006 269 274
28. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's disease and Alzheimer's disease brains Neurology 38 1988 1285 1291
29. G.E. Meredith, P.K. Sonsalla, and M.F. Chesselet Animal models of Parkinson's disease progression Acta Neuropathol. 115 4 2008 385 398
30. M. Mogi, A. Togari, K. Tanaka, N. Ogaw, H. Ichinose, and T. Nagatsu Caspase activities and tumor necrosis factor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain J. Neural. Transm. 107 2000 335 341 (Pubitemid 30162695)
31. T. Mosmann Rapid colorimetric assay for cellular growth survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
32. E. Mutez, A. Duhamel, L. Defebvre, R. Bordet, A. Destee, and A. Kreisler Lipid lowering drugs are associated with delayed onset and slower course of Parkinson's disease Pharmacol. Res. 60 1 2009 41 45
33. P. Naveilhan, I. Neveu, F. Jehan, C. Baudet, D. Wion, and P. Brachet Reactive oxygen species influence nerve growth factor synthesis in primary rat astrocytes J. Neurochem. 62 1994 2178 2186 (Pubitemid 24179496)
34. O. Neuhaus, S. Strasser-Fuchs, F. Fazekas, BC. Kieseier, G. Niederwieser, and HP Hartung Statins as immunomodulators. Comparison with interferon-β1b in MS Neurology 59 2002 990 997
35. K. Pahan, F.G. Sheikh, A.M. Namboodiri, and I. Singh Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages J. Clin. Invest. 100 1997 2671 2679 (Pubitemid 28007534)
36. G. Paxinos, C. Watson, M. Pennisi, and A. Topple Bregma., lamda and the interaural midpoint in sterotaxic surgery with rats of different sex, strain and weight J. Neurosci. Methods 13 2 1985 139 143 (Pubitemid 15008633)
37. J. Rodriguez-Pallares, J.A. Parga, A. Muñoz, P. Rey, M.J. Guerra, and J.L. Labandeira-Garcia Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons J. Neurochem. 103 1 2007 145 156 (Pubitemid 47404195)
38. A. Saner, and H. Thoenen Model experiments on the molecular mechanism of action of 6-hydroxydopamine Mol. Pharmacol. 7 1971 147 154
39. M. Santiago, M.C. Hernández-Romero, A. Machado, and J. Cano Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP does not Eur. J. Pharmacol. 609 2009 58 64
40. S. Schuster, A. Nadjar, J.T. Guo, Q. Li, C. Ittrich, B. Hengerer, and E. Bezard The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of LDOPA-induced abnormal involuntary movements in experimental Parkinson's disease J. Neurosci. 28 2008 4311 4316
41. M.L. Selley Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice Brain. Res. 1037 1-2 2005 1 6 (Pubitemid 40362375)
42. R. Stanislaus, A.K. Singh, and I. Singh Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis J. Neurosci. Res. 66 2001 155 162 (Pubitemid 32912284)
43. U. Ungerstedt 6-Hydroxy-dopamine induced degeneration of central monoamine neurons Eur. J. Pharmacol. 5 1968 107 110
44. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24 3 1970 485 493
45. U. Ungerstedt Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system Acta Physiol. Scand. Suppl. 367 1971 69 93
46. N. Vandjelovic, H. Zhu, H.P. Misra, R.P. Zimmerman, Z. Jia, and Y. Li EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin Mol. Cell Biochem. 364 1-2 2012 71 77
47. M. Vila, and S. Przedborski Targeting programmed cell death in neurodegenerative diseases Nat. Rev. Neurosci. 4 5 2003 365 375 (Pubitemid 37280175)
48. M. Vila, D. Ramonet, and C. Perier Mitochondrial alterations in Parkinson's disease: new clues J. Neurochem. 107 2 2008 317 328
49. A.H. Wagner, T. Kohler, U. Ruckschloss, I. Just, and M. Hecker Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation Arterioscler. Thromb. Vasc. Biol. 20 2000 61 69 (Pubitemid 30048347)
50. A.D. Wahner, J.M. Bronstein, Y.M. Bordelon, and B. Ritz Statin use and the risk of Parkinson disease Neurology 70 2008 1418 1422 (Pubitemid 351521934)
51. Q. Wang, W.L. Ting, H. Yang, and P.T. Wong High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase Br. J. Pharmacol. 144 7 2005 933 939 (Pubitemid 40593019)
52. Q. Wang, P.H. Wang, C. McLachlan, and P.T. Wong Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats Brain Res. 1045 1-2 2005 229 233 (Pubitemid 40725240)
53. S. Wassmann, U. Laufs, A.T. Baumer, K. Muller, C. Konkol, H. Sauer, M. Bohm, and G. Nickenig Inhibition of geranylgeranylation reduces angiotensin IImediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase Mol. Pharmacol. 59 2001 646 654 (Pubitemid 32179945)
54. P.S. Whitton Inflammation as a causative factor in the aetiology of Parkinson's disease Br. J. Pharmacol. 150 1997 963 976
55. E.D. Wills Mechanism of lipid peroxide formation in animal tissues Biochem. J. 99 1966 667 676
56. B Wolozin, S.W. Wang, N.C. Li, A. Lee, T.A. Lee, and L.E. Kazis Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease BMC Med. 5 2007 20
57. H. Yokoyama, R. Yano, E. Aoki, H. Kato, and T. Araki Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice Metab. Brain Dis. 23 2008 335 349
58. S. Youssef, O. Stuve, J.C. Patarroyo, P.J. Ruiz, J.L. Radosevich, and E.M. Hur The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 2002 78 84 (Pubitemid 35291443)